- Home
- GILD vs TJX Comparison
GILD vs TJX Comparison
Compare GILD & TJX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- TJX
- Stock Information
- Founded
- GILD 1987
- TJX 1962
- Country
- GILD United States
- TJX United States
- Employees
- GILD N/A
- TJX N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- TJX Clothing/Shoe/Accessory Stores
- Sector
- GILD Health Care
- TJX Consumer Discretionary
- Exchange
- GILD Nasdaq
- TJX Nasdaq
- Market Cap
- GILD 138.2B
- TJX 134.1B
- IPO Year
- GILD 1992
- TJX N/A
- Fundamental
- Price
- GILD $111.79
- TJX $118.20
- Analyst Decision
- GILD Buy
- TJX Strong Buy
- Analyst Count
- GILD 27
- TJX 17
- Target Price
- GILD $105.32
- TJX $135.06
- AVG Volume (30 Days)
- GILD 10.7M
- TJX 5.4M
- Earning Date
- GILD 04-24-2025
- TJX 05-21-2025
- Dividend Yield
- GILD 2.83%
- TJX 1.27%
- EPS Growth
- GILD N/A
- TJX 10.34
- EPS
- GILD 0.38
- TJX 4.26
- Revenue
- GILD $28,754,000,000.00
- TJX $56,360,000,000.00
- Revenue This Year
- GILD $1.77
- TJX $5.58
- Revenue Next Year
- GILD $3.52
- TJX $5.69
- P/E Ratio
- GILD $294.18
- TJX $27.75
- Revenue Growth
- GILD 6.04
- TJX 3.95
- 52 Week Low
- GILD $62.07
- TJX $92.35
- 52 Week High
- GILD $119.96
- TJX $128.00
- Technical
- Relative Strength Index (RSI)
- GILD 57.43
- TJX 46.94
- Support Level
- GILD $104.70
- TJX $119.33
- Resistance Level
- GILD $107.42
- TJX $121.34
- Average True Range (ATR)
- GILD 2.48
- TJX 2.11
- MACD
- GILD -0.62
- TJX 0.55
- Stochastic Oscillator
- GILD 57.74
- TJX 66.02
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About TJX TJX Companies Inc. (The)
TJX Companies is the leading off-price retailer of apparel, accessories, and home merchandise in the United States. The firm leverages its more than 20,000 global vendor relationships to procure and sell brand-name merchandise at prices 20%-60% cheaper than conventional retail channels. TJX opportunistically purchases excess inventory that stems from manufacturing overruns and retail closeout sales. The off-price retailer disperses its vast and disparate merchandise across its 5,000 global stores, creating a treasure-hunt shopping experience for consumers. Over three quarters of TJX's sales are derived from the United States, primarily via the T.J. Maxx, Marshalls, and HomeGoods banners. About 10% of sales are from Canada and 12% from Europe and Australia.